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The hematopoietic system is remarkably sensitive to injury, 
including radiation or chemotherapy. As such, radiation can 
lead to lymphocyte, neutrophil, erythrocyte, and platelet loss, 
disruption of tissue homeostasis, and organismal death from 
infection and/or hemorrhage. Thus, rapid and effective re-
generation of the hematopoietic system in response to injury 
is requisite for successful restoration of the hematopoietic 
tissue homeostasis and organismal survival. To this end, re-
cent studies have demonstrated that hematopoietic stem cells 
(HSCs) rarely proliferate in steady states. However, they ex-
pand greatly after transplantation or injury to guarantee ef-
ficient restoration of the hematopoietic system (Sun et al., 
2014; Busch et al., 2015; Säwén et al., 2016). As such, mech-
anistic understanding of such rapid hematopoietic stem and 
progenitor cell (HSPC) expansion would be beneficial for 
designing strategies achieving more efficient transplantation 
and hematopoietic regeneration.
ETS transcription factors have emerged as critical reg-
ulators of hematopoietic and vascular development (De Val 
and Black, 2009; Sumanas and Choi, 2016). In particular, Etv2 
(also known as Er71 and etsrp) performs a nonredundant and 
indispensable function in hematopoietic and vessel devel-
opment during embryogenesis, as Etv2 deficiency leads to a 
complete block in hematopoietic and vascular formation and 
embryonic lethality (Lee et al., 2008; Ferdous et al., 2009). 
Studies in zebrafish and Xenopus laevis have also demon-
strated the critical function of etv2 in blood and vessel forma-
tion (Sumanas and Lin, 2006; Sumanas et al., 2008; Neuhaus et 
al., 2010; Salanga et al., 2010). Importantly, Etv2 is transiently 
expressed in the primitive streak, yolk sac blood islands, and 
large vessels including the dorsal aorta during embryogenesis 
(Lee et al., 2008; Kataoka et al., 2011; Rasmussen et al., 2011; 
Wareing et al., 2012). Etv2 expression becomes undetectable 
once endothelial and hematopoietic cell lineages have been 
formed during embryogenesis. As such, hematopoietic and/
or endothelial deletion of Etv2 by using Tie2-Cre, VEC-Cre, 
or Vav-Cre leads to normal embryogenesis (Park et al., 2016), 
supporting the notion that Etv2 is only transiently required 
for the vessel and blood cell lineage formation. Consistently, 
Etv2 deletion by using Flk1-Cre leads to embryonic lethality 
because of insufficient hemangiogenic progenitor generation 
(Liu et al., 2015). Mechanistically, ETV2 positively activates 
genes critical for hematopoietic and endothelial cell lineage 
specification (Liu et al., 2012, 2015).
Despite its essential function in hematopoietic and 
vascular cell lineage development, studies investigating its 
role in adult hematopoiesis have been limiting. Notably, 
Etv2 deletion using the Mx1-Cre system and polyinosinic 
:polycytidylic acid (pIpC) administration led to seemingly 
rapid loss of HSC number and their hematopoietic 
reconstitution potential (Lee et al., 2011). Although this 
recent studies have established that hematopoietic stem cells (HScs) are quiescent in homeostatic conditions but undergo 
extensive cell cycle and expansion upon bone marrow (BM) transplantation or hematopoietic injury. the molecular basis for 
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study suggested its role in maintaining hematopoiesis in 
steady states, Tie2-Cre (hematopoietic and endothelial)– or 
Vav-Cre (hematopoietic)–mediated Etv2 deletion resulted 
in no appreciable hematopoietic phenotypes in steady states 
(Park et al., 2016). As the severe phenotype observed by Lee 
et al. (2011) could be caused by the combined effect between 
Etv2 loss and pIpC treatment, which perturbs steady-state 
hematopoiesis (Essers et al., 2009; Sato et al., 2009), we 
determined whether Etv2 might have an unexpected role in 
non–steady-state hematopoiesis. Specifically, we characterized 
hematopoietic regeneration in Etv2-deficient mice by using 
BM transplantation and 5-fluorouracil (5-FU)–mediated 
hematopoietic injury models. Our study demonstrated that 
although Etv2 was not essential for homeostatic hematopoiesis, 
it was reactivated upon injury and was required for HSPC 
proliferation to rapidly restore the hematopoietic system. 
We identify reactive oxygen species (ROS) as an upstream 
factor that activates Etv2 in injury. Without Etv2, HSPCs 
failed to expand, and mice succumbed to hematopoietic 
failure and death, revealing a critical role of this factor in 
hematopoietic regeneration. Importantly, we identify c-Kit as 
a downstream target that could rescue proliferation defects 
of the Etv2-deficient HSPCs in vitro and in short-term BM 
transplantation in vivo.
rESultS And dIScuSSIon
Etv2 is activated upon hematopoietic injury through roS
We previously reported that mature blood (B220+, 
Mac1+, Gr1+, Ter119+, CD4+, and CD8+) and HSPC 
(c-KIT+Sca1+Lin− [KSL]) cell populations in Tie2-Cre;Et-
v2f/f (herein Tie2-Cre;Etv2 CKO) mice were present at 
similar levels compared with controls (Park et al., 2016). 
Additional analysis for the frequency and absolute number 
of the lineage negative (Lin−), c-Kit+Sca1−Lin− (LK; pro-
genitor cell) and the CD150+CD48−KSL (KSL-SLAM 
[signaling lymphocytic activation molecule]; HSC) cell pop-
ulation in Tie2-Cre;Etv2 CKO BM revealed that they were 
also comparable with those of the littermate control mice 
(not depicted). Similarly, the common myeloid progenitor 
(CD34+CD16/32−LK), granulocyte-macrophage progeni-
tor (CD34+CD16/32+LK), and megakaryocyte-erythrocyte 
progenitor (CD34−CD16/32+LK) cell populations were also 
comparable in Tie2-Cre;Etv2 CKO and control BM (not 
depicted). These findings support the notion that Etv2 was 
dispensable for maintaining homeostatic hematopoiesis.
To determine whether Etv2 plays a role in nonho-
meostatic conditions, we assessed whether its expression was 
activated in HSPCs after hematopoietic injury, assuming its 
activation would have a role in regeneration. In particular, 
we assessed BM response to 5-FU treatment, as it depletes 
cycling hematopoietic cells and activates quiescent HSCs to 
proliferate and self-renew. Upon 5-FU injury, cycling he-
matopoietic cells are rapidly lost (days 1–5), hematopoietic 
regeneration ensues (days 6–11), and then homeostasis is re-
established (after day 20). Unexpectedly, Etv2 expression was 
readily detected in HSPCs, not in more committed progeni-
tor cells (Lin−c-Kit+Sca1−; not depicted), when examined 10 
d after 5-FU injection (Fig. 1 A). Additional key transcription 
factors controlling HSPC generation in development, Gata2, 
Scl, Fli1, and Runx1, were also up-regulated (Fig. 1 A). Im-
portantly, the kinetics of expression of these key genes, Etv2, 
Gata2, and Scl, coincided with that of the regeneration phase 
(Fig. 1 B). As tissue injury leads to ROS production and ROS 
is required for tissue regeneration (Gauron et al., 2013; Love et 
al., 2013), we determined whether 5-FU injury leads to ROS 
production and Etv2 activation in HSPCs. Remarkably, ROS 
levels were elevated in HSPCs during the regeneration phase 
after 5-FU treatment (days 9 and 10) but returned to normal 
levels by day 11 and remained low for the duration of the study 
(after day 13; Fig. 1 C). We saw slightly higher levels of ROS 
in Etv2-deficient HSPCs compared with controls at day 9, 
presumably because of proliferation defects in Etv2-deficient 
HSPCs leading to accumulation of the ROS generated (see 
the next section). Importantly, l-buthionine-S,R-sulfoximine 
(BSO), an inhibitor of glutathione biosynthesis, which leads 
to ROS production, increased intracellular ROS levels and 
Etv2 expression in HSPCs, suggesting that 5-FU injury leads 
to ROS production and Etv2 up-regulation in HSPCs (Fig. 1, 
D and E). Indeed, Etv2 expression remained low in HSPCs 
when N-acetyl cysteine (NAC; ROS scavenger) and apocynin 
(NAD PH [nicotinamide adenine dinucleotide phosphate re-
duced] oxidase inhibitor) were administered during recovery 
phase after 5-FU injury, demonstrating that ROS is upstream 
of Etv2 activation upon injury (Fig. 1 F).
Hematopoietic Etv2 but not endothelial Etv2 is critical for 
HSPc regeneration after 5-Fu injury
To evaluate the significance of the Etv2 activation in the 
regeneration capacity of HSPCs, we assessed the HSPC re-
covery potential in Tie2-Cre;Etv2 CKO mice after 5-FU 
injury (250 mg/kg). No significant difference in the BM 
cellularity was observed after 5-FU injection between con-
trol and CKO mice (not depicted). Whereas the KSL and 
CD150+CD48−KSL absolute cell number and frequency in 
control mice recovered by 11 d after 5-FU injury and reached 
homeostatic levels by day 21, Tie2-Cre;Etv2 CKO BM had 
reduced levels of HSPCs at days 10 and 11 (Fig. 2, A and B; 
Fig. S1). Despite the reduced HSPC recovery rate, HSPCs 
in Tie2-Cre;Etv2 CKO mice also reached the homeostatic 
levels by day 21 (Fig. 2, A and B). The reduced HSPC fre-
quency during the recovery phase, days 10 and 11, suggested 
lower proliferation rate of HSPCs. Thus, we assessed whether 
Etv2 deletion impacted HSPC proliferation. Specifically, we 
performed Ki67 and DAPI staining to determine the cell 
cycle status of the Etv2-deficient HSPCs. The percentage of 
KSL cells in the S-G2-M phase was slightly less, but statisti-
cally significant, in Tie2-Cre;Etv2 CKO mice compared with 
control mice at day 9 after 5-FU injury (Fig. 2 C). By day 
10, Etv2-deficient KSL cells had a similar percentage of cells 
in the S-G2-M phase compared with controls. Notably, the 
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percentage of CD150+CD48−KSL cells in the S-G2-M phase 
was greatly reduced in Tie2-Cre;Etv2 CKO mice during the 
recovery period after 5-FU injury (Fig. 2 D). These cells were 
mainly in the quiescent state (Fig. 2 E), suggesting that Etv2 is 
required for promoting HSC proliferation and regeneration.
The appreciable proliferation potential of the 
Etv2-deficient HSPC population (KSL; Fig. 2, A and C) sug-
gested that peripheral blood (PB) might recover relatively 
normally in Tie2-Cre;Etv2 CKO after 5-FU injury. Indeed, 
complete blood cell count data showed no substantial differ-
ences of the PB cell recovery between Tie2-Cre;Etv2 CKO 
and control mice after 5-FU injection (Fig. 2, F and G). BM 
and PB lineage analysis also showed that the frequency of B 
cells (B220+), T cells (CD3+), and myeloid cells (Gr1+ and 
Mac1+) was comparable between Tie2-Cre;Etv2 CKO and 
littermate controls (not depicted). However, we noticed that 
white blood cell counts in Tie2-Cre;Etv2 CKOs were lower 
at day 14 after 5-FU injury (Fig. 2 F). Moreover, about one 
half of the 5-FU–injected Tie2-Cre;Etv2 CKO mice, but not 
control mice, died after repeated blood drawing for PB analysis 
(not depicted). As the most primitive hematopoietic cell pop-
ulation displayed a notable defect in cell cycle/proliferation, it 
was possible that Tie2-Cre;Etv2 CKO mice might not man-
age stress requiring continued hematopoietic regeneration. 
Figure 1. Etv2 is activated upon hema-
topoietic injury through roS. (A) KSL cells 
were sorted from WT mice 10 d after vehicle 
(PBS) or 250 mg/kg 5-FU injection i.p. 20,000–
40,000 pooled KSL cells from each sample were 
subjected to RNA extraction and real-time 
PCR. Data are shown as a relative expression 
of Etv2, Gata2, Scl, Fli1, and Runx1 normalized 
to the vehicle-treated control group. n = 9 
from three independent experiments. (B) KSL 
cells were sorted at the indicated time points 
after 250 mg/kg 5-FU injection i.p. 20,000–
40,000 pooled KSL cells (Etv2) or whole BM 
(Scl and Gata2) were subjected to RNA ex-
traction and real-time PCR. Etv2, Gata2, and 
Scl expression normalized to GAP DH is shown. 
n = 4–6 from two independent experiments. 
(C) Tie2-Cre;Etv2 CKO mice or littermate con-
trol mice were injected with 250 mg/kg 5-FU 
i.p. or vehicle (PBS). DCF DA staining was per-
formed on KSL cells from days 0, 9, 10, 11, 13, 
and 21 after 5-FU injection. Data are expressed 
as a relative ROS level normalized to the litter-
mate control day-0 group. n = 6–9 from two 
independent experiments. (D and E) 40,000 KSL 
cells were cultured in a 24-well plate for 2 d 
with 10  µM BSO or vehicle, followed by DCF 
DA staining or real-time PCR analysis. Relative 
ROS levels and Etv2 expression in KSL cells 
were normalized to the vehicle control group. 
n = 6 from two independent experiments. (F) 
WT mice were injected with 250 mg/kg 5-FU 
i.p. or vehicle. Mice were treated with NAC 
and apocynin (APO) from days 4–10. 1 mg/ml 
NAC was added in the drinking water (changed 
every 3 d). 50 mg/kg apocynin was injected 
i.p. every day for 6 d starting from day 4. At 
day 10, 20,000–40,000 KSL cells were sorted 
for RNA extraction and quantitative RT-PCR. 
Data are expressed as a relative Etv2 expres-
sion normalized to the vehicle control group. 
n = 6 from two independent experiments. 
*, P < 0.05; **, P < 0.01. Error bars indicate 
standard error of the mean.
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Thus, we tested whether Etv2-deficient HSC proliferation 
defects could be manifested by repeated 5-FU injury. Specifi-
cally, we applied serial injection of 250 mg/kg 5-FU at an 11-d 
interval, an interval that showed maximal HSPC expansion in 
WT mice (Fig. 2, A–D), to continuously induce HSCs into 
cell cycle/proliferation. Tie2-Cre;Etv2 CKO mice started to 
die after the second 5-FU injection, and all mice died after 
the third 5-FU injection. In contrast, less than half of the 
control mice died after the third 5-FU injection (Fig. 2 H). 
At a less cytotoxic dose of 5-FU (150 mg/kg), 1 out of 10 
Tie2-Cre;Etv2 CKO mice died after the third 5-FU injec-
tion, whereas none of the littermate control mice died (not 
depicted). At a lower 5-FU dose (150 mg/kg), ROS levels 
were not significantly elevated in HSPCs, and Etv2-deficient 
HSPCs proliferated comparably with those from littermate 
controls (not depicted). These data suggested that, at extreme 
hematopoietic stress conditions, Etv2-deficient HSPCs, being 
defective in proliferative potential, might not meet the de-
mands of rapid restoration of the hematopoietic system.
To determine that the effect of Etv2 on HSPC pro-
liferation was hematopoietic cell intrinsic, we assessed the 
hematopoietic regeneration potential of Vav-Cre;Etv2f/f 
(Vav-Cre;Etv2 CKO) and VECadherin-Cre;Etv2f/f 
(VEC-Cre;Etv2 CKO) mice, which lack Etv2 in hematopoi-
etic and endothelial cells, respectively (Park et al., 2016). Etv2 
deletion was confirmed in BM CD45+ as well as KSL cells 
in both Vav-Cre;Etv2 and Tie2-Cre;Etv2 CKO mice but not 
in VEC-Cre;Etv2 CKO mice (not depicted). Additionally, 
complete Etv2 deletion was observed in CD31+CD45− en-
dothelial cells isolated from Tie2-Cre;Etv2 or VEC-cre;Etv2 
Figure 2. Impaired hematopoietic regeneration in tie2-cre;Etv2 cKo mice after 5-Fu treatment. (A–H) Tie2-Cre;Etv2 CKO mice or littermate 
control mice were injected with 250 mg/kg 5-FU i.p. or vehicle. (A and B) At days 0, 5, 8, 9, 10, 11, and 21 after 5-FU injection, the absolute number (per 
femur and tibia) of KSL or KSL-SLAM cells was determined by flow cytometry. n = 6 from two independent experiments. (C and D) At days 0, 9, 10, 11, and 
21 after 5-FU injection, the percentage of G0, G1, and S-G2-M phases in KSL or KSL-SLAM (CD150+CD48z− KSL) was determined by flow cytometry using 
surface markers Ki67 and DAPI staining. n = 6 from two independent experiments. (E) Cell cycle analysis of KSL-SLAM cells is shown at day 9. n = 6 from two 
independent experiments. (F and G) Complete blood cell count was analyzed by a Hemavet 950FS hematology system at days 0, 3, 7, 10, and 14 after 5-FU 
injection to determine white blood cells (WBCs) and RBCs. n = 10 from two independent experiments. (H) Tie2-Cre;Etv2 CKO mice and littermate control 
mice were injected with 250 mg/kg 5-FU i.p. for three times at an 11-d interval, and survival was monitored daily. A Kaplan-Meier survival curve of mice 
after 5-FU injury is shown. Time points of 5-FU injections are indicated on top with purple arrows. n = 10 from two independent experiments. *, P < 0.05; 
**, P < 0.01. Error bars indicate standard error of the mean.
o
n





Published May 1, 2017
5JEM
CKO lungs (not depicted). Etv2 deletion in KSL cells was 
not complete in Tie2-Cre;Etv2 CKO mice, even though 
these mice showed significantly diminished hematopoietic 
regeneration capacity. After 5-FU injury, BM cellularity was 
similar between control and CKO mice (not depicted). Im-
portantly, Vav-Cre;Etv2 CKO mice displayed similar HSPC 
recovery defects compared with Tie2-Cre;Etv2 CKO mice. 
VEC-Cre;Etv2 CKO mice exhibited comparable HSPC re-
covery as control mice (Fig. 3). These data suggest that hema-
topoietic Etv2 but not endothelial Etv2 is required for HSPC 
regeneration after 5-FU injury.
Hematopoietic Etv2 but not endothelial Etv2 is essential  
for hematopoietic reconstitution after transplantation
To further validate the hematopoietic cell–intrinsic role of 
Etv2 in HSPC regeneration, we used BM transplantation, 
which stimulates continuous long-term proliferation of 
HSPCs (Sun et al., 2014; Busch et al., 2015; Säwén et al., 
2016), to assess Etv2-deficient HSPCs for their hematopoietic 
reconstitution potential. Specifically, we performed compet-
itive transplantation experiments by mixing KSL cells from 
Vav-Cre;Etv2 CKO mice (CD45.2) and WT mice (CD45.1) 
at a 1:1 ratio and injecting them into lethally irradiated re-
cipients (CD45.1 × 45.2). Vav-Cre;Etv2 CKO KSL cells 
(CD45.2) showed very low PB contribution compared with 
competitive controls (Fig. 4, A and B). Vav-Cre;Etv2 CKO 
BM cells from the primary recipients showed similar defects 
in hematopoietic reconstitution in secondary transplantation 
(not depicted). Whole BM transplantation using Vav-Cre;Etv2 
CKO (CD45.2) and WT (CD45.1) mice (1:1 ratio) again 
showed very low PB contribution from Vav-Cre;Etv2 CKO 
mice compared with controls (not depicted). Etv2-deficient 
HSPCs displayed similar homing ability compared with WT 
HSPCs when injected retroorbitally and analyzed 4 h and 2 d 
after transplantation (not depicted). These data indicated that 
hematopoietic Etv2 was required for hematopoietic reconsti-
tution after transplantation.
To enforce the notion that Etv2 was required for the 
HSC-intrinsic manner, we performed competitive hemato-
poietic reconstitution studies by using VEC-Cre;Etv2 CKO 
Figure 3. Hematopoietic but not endothelial deletion of Etv2 impairs HSPc recovery after 5-Fu treatment. (A–I) Tie2-Cre;Etv2 CKO, VEC-Cre;Etv2 
CKO, Vav-Cre;Etv2 CKO, or littermate control mice were injected with 250 mg/kg 5-FU i.p. After 11 d, BM mononuclear cells were subjected to flow cytometry 
by using HSPC surface markers to determine absolute cell number (per femur and tibia) of different hematopoietic compartments. (A) Lin− cells. (B) KSL 
(c-Kit+Sca1+Lin−) cells. (C) Long-term HSCs (CD34−Flt3− KSL). (D) Short-term HSCs (CD34+Flt3− KSL). (E) Multipotent progenitor (CD34+Flt3+ KSL) cells. (F) 
LK (c-Kit+Sca1−Lin−) cells. (G) Common myeloid progenitor (CMP; CD34+CD16/32− LK) cells. (H) Granulocyte-macrophage progenitor (GMP; CD34+CD16/32+ 
LK) cells. (I) Megakaryocyte-erythrocyte progenitor (MEP; CD34−CD16/32− LK) cells. n = 4–6 from two independent experiments. *, P < 0.05; **, P < 0.001. 
Error bars indicate standard error of the mean.
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BM (CD45.2) and WT BM (CD45.1) cells (1:1 ratio) and 
lethally irradiated recipient mice (CD45.1 × 45.2). PB anal-
ysis showed that VEC-Cre;Etv2 CKO BM cells (CD45.2) 
had comparable contribution to PB compared with controls 
(Fig. 4 C). To further validate that endothelial Etv2 was dis-
pensable for HSPC regeneration potential, we additionally 
performed transplantation studies using WT BM (CD45.1 
× 45.2) as the donor and lethally irradiated WT (CD45.2) 
or VEC-Cre;Etv2 CKO mice (CD45.2) as recipients. 6 mo 
later, WT donor BM (CD45.1 × 45.2) was recovered from 
the WT or VEC-Cre;Etv2 CKO–recipient mice, mixed with 
fresh WT BM (CD45.1) in a ratio of 4:1, and transplanted 
into lethally irradiated recipients (CD45.2). PB analysis 
showed that WT BM (CD45.1 × 45.2) recovered from the 
VEC;Etv2 CKO mice had similar contribution compared 
with the WT BM (CD45.1 × 45.2) recovered from the WT 
mice (Fig. 4 D). These data demonstrate that endothelial Etv2 
was not required for maintaining HSPC function.
c-KIt signaling is downstream of EtV2 in promoting HSPc 
proliferation and recovery from 5-Fu injury
To understand the molecular mechanisms by which Etv2 reg-
ulates HSC regeneration, we examined previously published 
chromatin immunoprecipitation sequencing (ChIP-Seq) and 
microarray data (Liu et al., 2012, 2015) focusing on the genes 
in the regulation of cell proliferation categories. A great frac-
tion of the ETV2 ChIP-Seq peaks were associated with genes 
annotated as regulation of cell proliferation by gene ontol-
ogy (McLean et al., 2010), whose expression also changed by 
ETV2 status (Fig. 5 A). Among these, c-Kit expression was 
greatly up-regulated by enforced Etv2 expression, whereas 
its expression was significantly decreased by Etv2 deficiency 
Figure 4. Hematopoietic but not endothelial deletion of Etv2 results in decreased hematopoietic reconstitution capacity. (A and B) 10,000 KSL 
cells from Vav-Cre;Etv2 CKO or littermate control mice (both are CD45.2) were transplanted along with 106 competitor BM cells (CD45.1) into lethally ir-
radiated WT recipient mice (CD45.1 × CD45.2). PB from recipients was analyzed for donor-derived contribution by determining the percentage of CD45.1+ 
and CD45.2+ PB leukocyte or lymphoid (B220+/CD3+ or myeloid Gr1+) at the indicated time points after transplantation. n = 5–8 from two independent 
transplantations. (C) 106 BM cells from VEC-Cre;Etv2 CKO or littermate control mice (both are CD45.2) were transplanted along with 106 competitor BM cells 
(CD45.1) into lethally irradiated WT recipient mice (CD45.1 × CD45.2). PB from recipients was analyzed for donor-derived contribution by determining the 
percentage of CD45.1+ and CD45.2+ PB leukocytes at the indicated time points after transplantation. n = 10–13 from three independent transplantations. 
(D) 2 × 106 WT BM cells (CD45.1 × CD45.2) were transplanted into lethally irradiated WT or VEC-Cre;ETV2 CKO recipients (both are CD45.2). 6 mo after trans-
plantation, 2 × 106 BM cells (CD45.1 × CD45.2) recovered from WT or VEC-Cre;ETV2 CKO recipients were transplanted along with 5 × 105 competitor BM cells 
(CD45.1) into lethally irradiated recipient mice (CD45.2). PB was analyzed for donor-derived contribution by determining the percentage of CD45.1+CD45.2+ 
PB leukocytes at the indicated time points after transplantation. n = 3–6 from two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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(Fig.  5  B). ChIP-Seq data also identified potential ETV2 
binding sites in the c-Kit locus (Fig. S2), suggesting that 
c-Kit is downstream of ETV2. Thus, we determined whether 
ETV2-mediated c-Kit up-regulation was required for hema-
topoietic regeneration after BM injury. FACS analyses of the 
recovering BM after 5-FU injury demonstrated that c-KIT 
expression was dramatically up-regulated in Lin− cells during 
the regeneration phase in control mice (Fig. 5 C). Notably, its 
expression returned to normal levels once the hematopoietic 
system was restored, i.e. day 21. However, c-KIT expression 
levels in Lin− cells remained low during the recovery phase 
in Tie2-Cre;Etv2 CKO BM (Fig. 5 C). Baseline c-KIT ex-
pression in steady state was similar (not depicted). In culture, 
c-KIT+ cells had much higher proliferation rate than c-KIT− 
cells (Fig. 5 D). This suggested that Etv2 deficiency leads to 
defects in c-Kit up-regulation and c-KIT–mediated HSPC 
proliferation. To determine whether Etv2-mediated c-KIT 
up-regulation was indeed required for HSPC proliferation 
and hematopoietic regeneration after BM injury, we tested 
whether c-Kit expression could rescue the HSPC prolifer-
ation defects of the Tie2-Cre;Etv2 CKO BM. To this end, 
Tie2-Cre;Etv2 BM cells were isolated 8 d after 5-FU injury 
and infected with Etv2 or c-Kit lentivirus, and c-KIT expres-
sion, proliferation, and cell cycle of the infected cells were 
analyzed. As expected, Etv2 lentiviral infection dramatically 
rescued the frequency and numbers of c-KIT+ cells (Fig. 5, 
E–G). Moreover, c-Kit lentiviral infection also led to increased 
c-KIT+ cell frequency and numbers from the Etv2-deficient 
BM. To determine whether the rescue of the cell-surface 
phenotype, c-KIT+ cells, indeed reflected the functional res-
cue of the proliferation defects, we assessed BM cell recovery 
as well as the cell-cycle status of the c-Kit–infected cells. BM 
cell recovery and proliferation were significantly improved by 
Etv2 or c-Kit expression in Etv2-deficient BM (Fig. 5, E–G). 
Moreover, Etv2-deficient BM cells yielded a much higher 
percentage of cells in the S-G2-M phase after Etv2 or c-Kit 
lentiviral infection (Fig. 5 G). As expected, highly proliferat-
ing cells, i.e. cells in the S-G2-M phase, were enriched within 
c-KIT+ cells generated by Etv2 or c-Kit expression (Fig. 5 D). 
To determine whether c-Kit could rescue Etv2-deficient 
HSC defects in vivo, we collected Etv2-deficient BM cells 
7 d after 5-FU injury (CD45.2), infected them with Venus, 
Etv2, or c-Kit lentivirus, transplanted them into lethally irra-
diated recipient mice (CD45.1) together with mock-infected 
WT BM (CD45.1), and then analyzed them 3 d later for 
the total BM contribution and c-KIT+ cells generated. As 
shown (Fig. 5, H and I; and Fig. S3), total donor contribution 
(CD45.2+) as well as CD45.2+c-KIT+ cells were increased by 
either Etv2 or c-Kit expression compared with Venus control. 
These data collectively support the notion that c-KIT–medi-
ated HSPC proliferation was integral to ETV2-mediated BM 
recovery after injury.
In the present study, we uncover the unexpected role 
of Etv2 in hematopoietic regeneration. Upon hematopoietic 
injury, we discover that ROS levels are transiently increased 
in HSPCs and that Etv2 becomes transiently reactivated in 
HSPCs. Inhibition of ROS was sufficient to block Etv2 ac-
tivation in HSPCs upon injury. Etv2 was necessary to ensure 
efficient hematopoietic regeneration after hematopoietic in-
jury. As such, we propose that although Etv2 is dispensable 
for maintaining HSCs in steady states, it is required for emer-
gency hematopoiesis. Surprisingly, despite its critical role in 
vascular regeneration (Park et al., 2016), we found that Etv2 
was dispensable in the endothelial cell niche for maintaining 
HSCs in the steady state or injury.
Recent studies have established that ROS is critical 
for tissue regeneration. In particular, in the Xenopus tadpole 
tail regeneration model, tail amputation leads to rapid ROS 
production, which activates Wnt/β-catenin and FGF20 sig-
naling and tail regeneration (Love et al., 2013). In the ze-
brafish fin–amputation regeneration model, ROS is again 
rapidly produced in regenerating tissue and triggers compen-
satory proliferation of stump epidermal cells (Gauron et al., 
2013). ROS positively regulate mouse spermatogonial stem 
cell self-renewal through stress kinases p38 MAPK and JNK 
pathways (Morimoto et al., 2013). ROS is also required for 
neuroregeneration in newts and planarian (Hameed et al., 
2015; Pirotte et al., 2015). Intriguingly, ROS role in HSCs 
seem controversial (Ito et al., 2006; Ludin et al., 2014; Wal-
ter et al., 2015; Itkin et al., 2016). In particular, activation of 
the ROS–p38 MAPK pathway appears to be detrimental for 
HSCs (Ito et al., 2006; Walter et al., 2015). However, a condi-
tional p38α deletion study has revealed that it is necessary for 
HSC regeneration in stress response (Karigane et al., 2016). 
It is important to note that ROS levels were transiently ele-
vated in HSPCs during regeneration phase, which might be 
the key to successful HSC regeneration. Future studies will 
require detailed mechanistic understanding of ROS and Etv2 
activation in relationship to p38 MAPK that contributes to 
hematopoietic regeneration.
KIT ligand and c-KIT interaction between the stromal 
niche and HSCs is critical for maintaining HSPCs in adults 
(Geissler et al., 1988; Huang et al., 1990; Matsui et al., 1990; 
Thorén et al., 2008; Kimura et al., 2011; Ding et al., 2012). 
Importantly, c-KIT levels on HSCs determine the outcome 
of the HSC fate (Grinenko et al., 2014; Shin et al., 2014). 
Specifically, HSCs expressing high levels of c-KIT cannot 
contribute to long-term hematopoietic reconstitution, as 
they proliferate more robustly and differentiate upon trans-
plantation. However, HSCs with low levels of c-KIT were 
able to contribute to long-term hematopoietic reconstitu-
tion. Our data suggest that c-Kit is downstream of ETV2 and 
responsible for HSPC proliferation during hematopoietic 
recovery. In particular, c-KIT expression remained low in 
Etv2-deficient HSPCs during recovery, and the c-Kit gene 
delivery could rescue proliferation defects of Etv2-deficient 
HSPCs in vitro and in short-term BM transplantation in 
vivo. However, c-Kit gene delivery failed to rescue the 
long-term repopulation potential of Etv2-deficient HSPCs 
(unpublished data). This outcome is reminiscent of the stud-
o
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Figure 5. c-Kit is an EtV2 downstream target and responsible for EtV2-mediated HSPc recovery after 5-Fu treatment. (A) Among 121 genes 
that were identified as putative direct targets of ETV2 in differentiated embryonic stem cells by Liu et al. (2015), 17 genes, including c-Kit, were annotated 
as genes related to regulation of cell proliferation. P-value was estimated using hypergeometric distribution. (B) Relative c-Kit expression levels, determined 
by microarray, in control, Etv2−/−, or Etv2-overexpressing embryoid body (in vitro differentiated embryonic stem) cells is shown (Liu et al., 2012). n = 2. 
(C) Tie2-Cre;Etv2 CKO or littermate control mice were injected with 250 mg/kg 5-FU i.p. At days 0, 9, 10, 11, and 21, flow cytometry with surface marker 
staining was performed to determine c-KIT expression levels on Lin− cells after 5-FU injury. Data are expressed as a relative c-KIT expression normalized 
to the littermate control day-0 group. n = 3–5 from two independent experiments. (D–G) Tie2-Cre;Etv2 CKO or littermate control mice were injected with 
250 mg/kg 5-FU. BM mononuclear cells were collected 8 d later and infected with Venus, Etv2, or c-Kit lentivirus for 1 d, followed by cell count and flow 
cytometry analysis. Cell count was determined by using the CCK8 kit. Five different experimental groups are shown. Blue, control (no 5-FU); green, control 
+ 5-FU; yellow, Tie2-Cre;Etv2 CKO + 5-FU + lentivirus-Venus (Venus expressing control lentivirus); cyan, Tie2-Cre;Etv2 CKO + 5-FU + lentivirus Etv2; and 
red, Tie2-Cre;Etv2 CKO + 5-FU + lentivirus c-Kit. (D) The percentage of c-KIT− and c-KIT+ cells in the S-G2-M phase in each group is shown. n = 9 from 
three independent experiments. (E) The frequency of c-KIT–positive cell population in each group is shown. n = 9 from three independent experiments. 
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ies by Shin et al. (2014) and Grinenko et al. (2014), which 
demonstrated that high c-KIT expression leads to deficits 
in long-term reconstitution potential. Presumably, lentiviral 
c-Kit expression in Etv2 KO KSL cells that resulted in high 
c-KIT expression levels might have caused rescue failure of 
the long-term repopulation potential. Alternatively, it is also 
possible that additional ETV2 downstream signaling might 
be required for rescue of long-term repopulation poten-
tial. Future studies on the relationship between ROS and 
Etv2 activation as well as c-Kit regulation mechanisms are 
warranted. In conclusion, our research may provide a novel 
potential target for improving hematopoietic recovery after 
chemotherapy and hematopoietic transplantation.
MAtErIAlS And MEtHodS
Mice
The generation of Tie2-Cre;Etv2f/f, VEC-Cre;Etv2f/f, and 
Vav-Cre;Etv2f/f mice has been previously described (Park 
et al., 2016). In brief, Tie2-Cre;Etv2f/+, VEC-Cre;Etv2f/+, 
or Vav-Cre;Etv2f/+ mice were mated with Etv2f/f to ob-
tain Tie2-Cre;Etv2f/f, VEC-Cre;Etv2f/f, or Vav-Cre;Etv2f/f 
mice. Cre+;Etv2f/+, Cre−;Evt2f/+, or Cre−;Etv2f/f littermates 
were used as controls. Animal husbandry, generation, and 
handling were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Com-
mittee of Washington University School of Medical in St. 
Louis. Information on genotyping primers was previously 
described (Park et al., 2016).
competitive BM transplantation
Recipient mice were lethally irradiated (9.5 Gy; single 
dose) 1 d before cell transplantation. For primary com-
petitive transplantation, 106 donor BM cells or 104 donor 
sorted HSPCs (KSL) cells (all are CD45.2) from Vav-
Cre;Etv2 CKO or VEC-Cre;Etv2 CKO mice were trans-
planted along with 106 BM cells or 104 sorted KSL cells 
as competitor cells from WT mice (CD45.1). The cell sus-
pensions in a 100-µl volume of PBS were injected into 
lethally irradiated recipients (CD45.1 × CD45.2) through 
the retroorbital sinus. In assessing Etv2 for its endothe-
lial niche requirements, 2 × 106 WT BM cells (CD45.1 
× CD45.2) were transplanted into lethally irradiated WT 
recipients or VEC-Cre;Etv2 CKO recipients (both are 
CD45.2). 6 mo after primary transplantation, BM was re-
covered from the primary recipients, and then, 2 × 106 
BM cells (CD45.1 × CD45.2) from primary recipients 
were transplanted along with 5 × 105 competitor BM 
cells (CD45.1) through the retroorbital sinus. PB from 
recipients was analyzed for donor-derived hematopoiesis 
by determining the percentage of CD45.1+, CD45.2+, or 
CD45.1+/CD45.2+ PB leukocytes every 4 wk.
5-Fu treatment
Control or Etv2 CKO mice were injected i.p. with a single 
dose of 5-FU (150 mg/kg or 250 mg/kg; Sigma-Aldrich) 
or vehicle control (sterile PBS). In serial 5-FU experiments, 
mice were injected (250 mg/kg each time) for three times at 
an interval of 11 d. Survival was monitored daily.
complete blood cell count with differential
PB was obtained by retroorbital collection from WT or 
Tie2-Cre;Etv2 CKO mice at days 0, 3, 7, 10, and 14 after 
one dose of 250-mg/kg 5-FU injection i.p. Whole PB cell 
counts were analyzed using a hematology system (Hemavet 
950FS; Drew Scientific).
Flow cytometry and cell sorting
BM cells were prepared by centrifuging femur and tibia 
at 12,000 g for 1 min. All collected cells were treated with 
ACK red blood cell lysis buffer (Gibco; Thermo Fisher Sci-
entific) before analyses. mAbs against c-Kit (2B8), Sca1 (D7), 
CD3e (17A2), B220 (RA3-6B2), Ter119 (TER-119), Gr1 
(RB6-8C5), CD16/32 (93), CD34 (RAM34), Flt3 (A2F10), 
CD150 (c15-12f12.2), CD48 (HM48-1), CD45.1 (A20), 
CD45.2 (104), and Ki67 (B56) were purchased from BD, 
BioLegend, or eBioscience. Flow cytometric analysis was 
performed using an LSRFortessa X-20 or FAC SCA NTO 
II flow cytometer (BD).
For cell sorting, BM cells were stained with mAbs against 
CD3, B220, Gr1, and Ter119 lineage markers, followed by 
negative selection of lineage-negative cells using a magnetic- 
activated cell-sorting kit (Miltenyi Biotec). Lin−-enriched 
BM cells were stained with mAbs against lineage markers 
(CD3, B220, Gr1, and Ter119), c-Kit, and Sca1, and KSL cells 
were sorted using a FAC SAria II flow cytometer (BD).
For cell cycle analysis, BM cells were stained using mAbs 
against c-Kit, Sca1, CD48, CD150, and lineage markers and 
fixed/permeabilized using Cytofix/Cytoperm (BD). Then, 
cells were stained with Ki67 and DAPI and analyzed using 
an LSR Fortessa X-20 or FAC SCA NTO II flow cytometer. 
Ki67−DAPI− cells were considered to be in G0, Ki67+DAPI− 
cells in G1, and Ki67+DAPI+ cells in S-G2-M.
(F) The relative percentage of the cell counts in each group normalized to control (no 5-FU injury) is shown. n = 9 from three independent experiments. 
(G) The percentage of cells in the S-G2-M phase in each group is shown. n = 9 from three independent experiments. (H and I) Tie2-Cre;Etv2f/f or littermate 
control mice (CD45.2) were injected with 250 mg/kg 5-FU i.p. 7 d after injection, and 20,000 BM mononuclear cells were isolated and seeded onto a V-shape 
96-well plate and infected with either lenti-Venus, -Etv2, or –c-Kit. Littermate control BM mononuclear cells were infected with lenti-Venus only. On the 
second day, cells were transplanted into 9 Gy–irradiated recipient mice (CD45.1) together with 20,000 mock-infected WT BM cells (CD45.1). Donor contri-
bution (CD45.2) and c-Kit–positive cells from BM were analyzed by flow cytometry with surface marker and CD45.1 and CD45.2 3 d after transplantation. 
n = 6 from two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars indicate standard deviations.
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KSl cell culture and roS detection
Sorted KSL cells were cultured in 24-well tissue culture 
plates (20,000 cells/well) in media containing StemSpan 
serum-free base medium (STE MCE LL Technologies), 
10% serum (Hyclone), KitL (1% supernatant), Flt3L (1% 
supernatant), IL-3 (1% supernatant), and thrombopoietin 
(10 ng/ml; R&D Systems) in the presence or absence of 
200  µM BSO (Sigma-Aldrich) for 2 d. ROS levels were 
measured by flow cytometry using 1–5  µM 2′-7′-dichlo-
rodihydrofluorescein diacetate (DCF DA; Sigma-Aldrich) 
staining. Median of fluorescence intensity was used to assess 
the relative ROS content.
lentiviral production and infection
293FT cells were transfected with CSII-EF-MCS-IRES-VEN 
US, pHIV-MND-IRES–c-Kit, or CSII-EF-MCS-IRES-Etv2, 
pCAG-HIVgp, and pCMV-VSV-G-RSV-Rev (4:3:1) by using 
the calcium phosphate method. c-Kit lentiviral vector was 
obtained from G. Challen (Washington University, St. Louis, 
MO). 16 h after transfection, the media was changed, and cells 
were cultured for an additional 48 h. Subsequently, supernatant 
was harvested and concentrated using a Lenti-X-Concentrator 
(Takara Bio Inc.). The virus titer was determined by the Len-
ti-X p24 Rapid Titer kit (Takara Bio Inc.). Virus titer was ∼3 
× 107 infectious units per milliliter. 105 BM cells were seeded 
into a 24-well plate and infected with 106 virus particles mixed 
with 8 µg/ml polybrene (Sigma-Aldrich).
Quantitative rt-Pcr
KSL cells sorted from control or 5-FU–treated mice were 
pooled and used (two to three were pooled as a sample). 
An RNeasy Micro kit (QIA GEN) was used for RNA ex-
traction according to the manufacturer’s instruction. cDNA 
was prepared by using qScipt cDNA SuperMix (Quanta Bio-
sciences) according to the manufacturer’s protocol. Quantita-
tive real-time PCR primers for Etv2, Gata2, Scl, Fli1, Runx1, 
β-actin, and Gapdh used in this study are described in our 
previous studies (Liu et al., 2015; Park et al., 2016).
Statistical analysis
Student t test (Prism5; GraphPad Software) was used for sta-
tistical analysis of most in vitro and in vivo experiments. For 
survival analysis, log-rank test or Gehan-Breslow-Wilson test 
was used for statistical analysis. A p-value <0.05 was con-
sidered to be significant.
online supplemental material
Fig. S1 shows representative FACS analysis for HSPC subsets. 
Fig. S2 shows two potential ETV2 binding sites and the cor-
responding sequence within the c-Kit locus. Fig. S3 shows 
representative FACS analysis of c-Kit expression.
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Figure S1. Etv2 cKo mice display defects in hematopoietic recovery after 5-Fu injury (related to Fig. 2). Representative FACS plots of the KSL 
(c-Kit+Sca1+Lin−) and KSL-SLAM (CD48−CD150+ KSL) analysis in Tie2-Cre;Etv2 CKO or control mice after 5-FU treatment are shown. Numbers in the boxes 
indicate the frequency of KSL cells (left) and CD150+CD48− KSL cells (right).
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Figure S2. the potential binding sites of EtV2 in the c-Kit locus are shown (related to Fig. 5). Two potential ETV2-binding peaks and the corre-
sponding sequences, identified from the ChIP-Seq analysis, are shown (Liu et al., 2015). TSS, transcription start site.
Figure S3. c-Kit is downstream of EtV2 in hematopoietic regeneration (related to Fig. 5). (A) Representative FACS plots showing the percentage of 
c-KIT+Linlow/− cells recovered from the culture after infection with lenti-Venus, -Etv2, or –c-Kit virus. (B) Representative FACS plots showing the percentage 
of donor contribution and CD45.2 and c-KIT+ cells is shown. BM from Tie2-Cre;Etv2f/f mice were obtained 7 d after 5-FU injection, infected with lenti-Venus, 
-Etv2, or –c-Kit, and then competitively transplanted with mock-infected WT BM into 9 Gy–irradiated recipient mice (CD45.1). Littermate control BM was 
used as the positive control. BM was analyzed 3 d later.
